Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification

Executive Summary

Merck will use the need for added therapies as a measure to determine rebate value – one that might be more straightforward than monitoring hemoglobin A1C data.


Related Content

The Outcomes-Based Reimbursement Experiment
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA
Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority
Novartis To Payers: Entresto Works Or You Get A Discount


Related Companies